Conditions: Neuroendocrine Tumour With Carcinoid Symptoms
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 26
Healthy volunteers: no

Brief summary:
The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.

Detailed description:

Arms:

Interventions: intervention 1: lanreotide (Autogel formulation)
Intervention descriptions: intervention 1: 90 mg or 120 mg once every 28th day

Protocol document: